Group 1 - The core viewpoint of the news is the release of the "Several Measures to Support the High-Quality Development of Innovative Drugs" by the National Medical Insurance Administration and the National Health Commission, which includes 16 measures to support the entire chain of innovative drug research and development, access, clinical use, and multi-payment systems [1] Group 2 - In terms of supporting innovative drug research and development, the measures emphasize the use of medical insurance data for R&D, fostering patient capital for innovative drugs, and enhancing policy guidance for drug access [1] - Regarding medical insurance access, the measures propose to reasonably determine the payment standards for innovative drugs, considering factors such as the burden on the insurance fund, clinical needs, patient benefits, market competition, and R&D investment [1] - The establishment of a commercial insurance innovative drug directory is highlighted as a significant step towards integrating basic medical insurance and commercial insurance, thereby improving the multi-tiered medication guarantee system [2] Group 3 - The commercial insurance innovative drug directory will allow for the inclusion of innovative drugs that exceed the basic insurance coverage, thus providing more development space for commercial health insurance [2] - The process for establishing the commercial insurance innovative drug directory will involve the National Medical Insurance Administration and will aim to reduce the administrative burden on companies by allowing simultaneous applications with the medical insurance directory [2][3] - The commercial insurance directory will respect the market position of commercial insurance companies, allowing them significant decision-making power in the evaluation and pricing of drugs [3]

Core Viewpoint - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, addressing challenges in research and development, insurance coverage, hospital usage, and payment pressures [1][5]. Group 1: Innovative Drug Development Support - A comprehensive support system for innovative drug development has been established, utilizing healthcare insurance data to enhance research efficiency and direction [5]. - The measures encourage commercial health insurance companies to invest in innovative drug development through various financial channels, addressing the long funding cycles and high capital needs of R&D [5][6]. Group 2: Establishment of Commercial Health Insurance Innovative Drug Directory - The introduction of a "Commercial Health Insurance Innovative Drug Directory" is a significant breakthrough, allowing for simultaneous application and adjustment with the basic medical insurance directory [8][9]. - The directory will focus on innovative drugs with high clinical value and significant patient benefits, providing a clearer boundary for basic medical insurance and enhancing the development space for commercial health insurance [9][10]. Group 3: Market Entry and Clinical Application - The measures streamline the process for innovative drugs to enter the market, allowing for more flexible and efficient listing procedures [10]. - Medical institutions are required to adjust their drug inventories promptly after updates to the drug directory, ensuring timely access to innovative drugs for clinical needs [10][11]. Group 4: Payment Management and Regulation - The payment management for innovative drugs has been refined, allowing medical institutions to apply for special cases where standard payment methods are not suitable [11]. - The measures emphasize the importance of regulatory oversight on healthcare funds, ensuring that innovative drug payments are included in the key areas of fund supervision [11].